Alvotech was founded in 2013, with the mission to create a company focused on becoming a pure play biosimilar leader, specialized in the development and manufacturing of biosimilar monoclonal antibodies for global markets.
We are passionate about transforming patients’ lives by increasing access to these life changing therapies. Our focus is on bringing to market high quality lower cost alternatives through our integrated development and manufacturing platform.
In our short history, we have created a uniquely positioned biopharmaceutical company that focuses purely on the biosimilar market with complete vertical integration from early R&D to commercial manufacturing with subsidiaries in four European countries.
Our in house R&D platform drives the timely development of our strong pipeline and our state-of-the-art flexible biomanufacturing facility ensures high quality and cost effective production.
A great team of almost 250 professionals share our passion to be part of this journey. Through dedication and hard work we will become a leading global biosimilar company.
Our commitment to our partners is to be the best, most flexible supplier, with the capability to adapt to changing market demands. These elements are the key to Alvotech’s success.
Meet us at .
Please tell us a little about yourself.